Start Time: 16:30 January 1, 0000 5:12 PM ET Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2020 Earnings Conference Call November 05, 2020, 16:30 PM ET Company Participants Antony Mattessich - President and CEO Michael Goldstein - CMO Patricia Kitchen - COO Donald Notman - CFO Conference Call Participants Dane Leone - Raymond James Joseph Catanzaro - Piper Sandler Jonathan Wolleben - JMP Securities Edward Chung - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. Thank you for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 (Mark One) Ocular Therapeutix, Inc. ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) For the quarterly period ended September 30, 2020 Delaware 20-5560161 ...

(N A S DA Q : O C UL ) TRANSFORMING DRUG DELIVERY LEVERAGING A NOVEL TECHNOLOGY PLATFORM ANTONY MATTESSICH, CHIEF EXECUTIVE OFFICER MICHAEL GOLDSTEIN, MD, CHIEF MEDICAL OFFICER September 2020 FORWARD LOOKING STATEMENTS Any statements in this presentation about future expectations, plans, and prospects for the Company, including the commercialization of DEXTENZA®, ReSure® Sealant, or any of the Company's product candidates; the commercial launch of, and effectiveness of reimbursement codes for, DEXTENZA; the ...

(NASDAQ: OCUL) TRANSFORMING DRUG DELIVERY LEVERAGING A NOVEL TECHNOLOGY PLATFORM ANTONY MATTESSICH, CHIEF EXECUTIVE OFFICER September 2020 FORWARD LOOKING STATEMENTS Any statements in this presentation about future expectations, plans, and prospects for the Company, including the commercialization of DEXTENZA®, ReSure® Sealant, or any of the Company's product candidates; the commercial launch of, and effectiveness of reimbursement codes for, DEXTENZA; the development and regulatory status of the Company's p ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2020 Earnings Conference Call August 7, 2020 8:30 AM ET Company Participants Donald Notman - CFO Antony Mattessich - President, CEO & Director Michael Goldstein - Chief Medical Officer Conference Call Participants Joseph Catanzaro - Piper Sandler & Co. Yi Chen - H.C. Wainwright & Co. Dane Leone - Raymond James & Associates Jonathan Wolleben - JMP Securities Operator Good Morning, ladies and gentlemen. Thank you for standing by, and welcome to the Ocular Therapeutix ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdic ...

Ocular Therapeutix (NASDAQ:OCUL) Q1 2020 Results Conference Call May 8, 2020 8:30 AM ET Company Participants Donald Notman - CFO Antony Mattessich - President and CEO Dr. Michael Goldstein - Chief Medical Officer Conference Call Participants Joe Catanzaro - Piper Sandler Stacy Ku - Cowen & Co. Jonathan Wolleben - JMP Securities Boobalan Pachaiyappan - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by and welcome to the First Quarter 2020 Ocular Therapeutix Earnings Conference Call. At ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5560161 (St ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2019 Earnings Conference Call March 12, 2020 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President and Chief Executive Officer Michael Goldstein - Chief Medical Officer Scott Corning - Senior Vice President, Commercial Conference Call Participants Joe Catanzaro - Piper Jaffray Dane Leone - Raymond James & Associates, Inc. Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. Thank you for standing by ...

Table of Contents For the transition period from to Commission file number 001-36554 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20- 5560161 (State o ...